Core Viewpoint - The medical device sector experienced a slight decline of 0.31% on November 6, with Danaher Biomedical leading the losses, while the overall market indices showed gains, with the Shanghai Composite Index up by 0.97% and the Shenzhen Component Index up by 1.73% [1][2]. Group 1: Market Performance - The Shanghai Composite Index closed at 4007.76, increasing by 0.97% [1]. - The Shenzhen Component Index closed at 13452.42, increasing by 1.73% [1]. - The medical device sector saw a net outflow of 638 million yuan from major funds, while retail investors contributed a net inflow of 446 million yuan [2][3]. Group 2: Individual Stock Performance - Hualan Co., Ltd. (301093) saw a significant increase of 8.53%, closing at 44.00 yuan with a trading volume of 67,500 shares and a transaction value of 293 million yuan [1]. - Danaher Biomedical (920009) led the declines with a drop of 4.69%, closing at 83.50 yuan and a trading volume of 24,900 shares, resulting in a transaction value of 206 million yuan [2]. - Other notable gainers included Furuida (300049) with a 4.32% increase and a closing price of 74.56 yuan, and Kangzhong Medical (688607) with a 3.04% increase, closing at 29.81 yuan [1][2]. Group 3: Fund Flow Analysis - Major funds showed a net outflow in several stocks, including Furuida with a net outflow of 23.99 million yuan, while retail investors showed a net inflow of 25.27 million yuan [3]. - Dongfulong (300171) experienced a net inflow of 21.17 million yuan from major funds, indicating positive sentiment towards the stock [3]. - The overall trend indicates a mixed sentiment in the medical device sector, with some stocks attracting retail interest despite the overall outflow from major funds [2][3].

Core Insights - 康为世纪 is a leading provider of molecular detection solutions in China, established in 2010 and listed on the Shanghai Stock Exchange in 2022 [1] Financial Performance - In Q3 2025, 康为世纪 reported revenue of 140 million yuan, ranking 36th among 39 companies in the industry, with the industry leader generating 3.428 billion yuan [2] - The company's net profit for the same period was -78.1 million yuan, placing it 31st in the industry, while the top performer reported a net profit of 1.588 billion yuan [2] Profitability and Debt - 康为世纪's debt-to-asset ratio was 9.14% in Q3 2025, lower than the industry average of 18.29% [3] - The gross profit margin for the company was 49.78%, which is below the industry average of 56.20% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.11% to 3,905, while the average number of circulating A-shares held per shareholder increased by 1.13% to 9,729.41 [5] - The largest circulating shareholder, 融通健康产业灵活配置混合A/B, reduced its holdings by 1 million shares [5] Executive Compensation - The chairman and general manager, 王春香, received a salary of 1.205 million yuan in 2024, a decrease of 160,000 yuan from 2023 [4]

Core Insights - The company reported a revenue of 140 million yuan for the first three quarters of 2025, representing a year-on-year growth of 42.01% [1] - The company experienced a net loss attributable to shareholders of 76.16 million yuan [1] - The company's net profit excluding non-recurring items was a loss of 93.91 million yuan [1] - The basic earnings per share were reported at -0.69 yuan [1]

Core Viewpoint - Kangwei Century (688426.SH) reported a significant increase in revenue for the first three quarters of 2025, indicating strong growth potential despite ongoing losses [1] Financial Performance - The company achieved total operating revenue of 140 million yuan, representing a year-on-year increase of 42.01% [1] - The net profit attributable to shareholders of the parent company was -76.1626 million yuan, which is a reduction in losses by 19.4888 million yuan compared to the same period last year [1] - The basic earnings per share stood at -0.69 yuan [1]

证券代码：688426 证券简称：康为世纪 公告编号：2025-043 江苏康为世纪生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●会议召开时间：2025 年 11 月 10 日（星期一）下午 16:00-17:00 1 / 3 ●会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com） ●会议召开方式：上证路演中心网络互动 ●投资者可于 2025 年 11 月 3 日（星期一）至 2025 年 11 月 7 日（星期五）中午 12:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IRM@cwbio.cn 进行提问。公司将在本次业绩说明会上对投资者普遍关注的、有代表性的问题逐条进行 回答。 江苏康为世纪生物科技股份有限公司(下称"公司")已于 2025 年 10 月 31 日在上海证 券交易所网站（www.sse.com.cn）披露了《2025 年第三季度报告》，为了 ...

江苏康为世纪生物科技股份有限公司 2025 年第三季度报告 证券代码：688426 证券简称：康为世纪 江苏康为世纪生物科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 1 / 13 单位：元 币种：人民币 项目 本报告期 本报告期比 上年同期增 减变动幅度 (%) 年初至报告期末 年初至报告期 末比上年同期 增减变动幅度 (%) 营业收入 52,455,562.72 68.47 139,574,234.46 42.01 利润总额 -21,249,963.37 54.96 -81,880,016.30 21.98 归属于上市公司股东的 净 ...

证券代码：688426 证券简称：康为世纪 公告编号：2025-042 江苏康为世纪生物科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 10 月 29 日 （二） 股东会召开的地点：江苏省泰州市医药高新区泽兰路 18 号江苏康为世纪 生物科技股份有限公司 2 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 35 | | --- | --- | | 普通股股东人数 | 35 | | 2、出席会议的股东所持有的表决权数量 | 78,019,730 | | 普通股股东所持有表决权数量 | 78,019,730 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 70.9710 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 7 ...

致:江苏康为世纪生物科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受江苏康为世纪生物科技股份有限 公司(以下简称"公司")的委托,指派本所茹秋乐律师、周奇律师(以下简称"本所 律师")根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会 规则》等法律、法规以及规范性文件(以下统称"法律法规")及《江苏康为世纪生物 科技股份有限公司章程》(以下简称"公司章程")的规定就公司 2025 年第二次临时 股东会(以下简称"本次股东会")相关事宜出具法律意见。 上海市通力律师事务所关于江苏康为世纪生物科技股份有限公司 2025 年第二次临时股东会的法律意见书 香港 HONG KONG 伦敦 LONDON 本所及本所律师依据法律法规及本法律意见出具目以前已经发生或者存在的事实, 严格履行了法定职责,遵循了勤勉尽责和诚实信用原则,进行了充分的核查验证,保证 本法律意见所认定的事实真实、准确、完整,所发表的结论性意见合法、准确,不存在 虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 本所律师已经对公司提供的与本次股东会有关的法律文件及其他文件、资料予以了 核查、验证。在进行核查验证过程中 ...

Core Insights - As of October 24, a total of 98 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stock with the longest streak of net buying is Yibin Paper, which has seen net buying for 11 consecutive trading days [1] - Other notable stocks with significant net buying days include Juxing Technology, Laofengxiang, Kangwei Century, Tebao Biological, Daimei Co., Zhejiang Wenhu Internet, Huakang Clean, and Fuyuan Medical [1]

Core Insights - A total of 73 stocks in the Shanghai and Shenzhen markets have received net buying from major funds for five consecutive days or more as of October 23 [1] - The stock with the longest consecutive net buying days is Yongmaotai, which has seen net buying for 11 consecutive trading days [1] - Other notable stocks with significant net buying days include Yibin Paper, Hanghua Co., Baofeng Energy, Laofengxiang, Juxing Technology, Naxinwei, Daimei Co., and Kangwei Century [1]